Fulgent Genetics stock rating upgraded to Buy at UBS on growth potential

UBS upgraded Fulgent Genetics (FLGT) to Buy and raised its price target to $30, citing the company's strong financial position, share gain opportunities in its Precision Diagnostics segment, and recovering Anatomic Pathology business, with expectations for 10% revenue growth from 2025. This upgrade follows the company's Q2 2025 earnings, which reported an $81.8 million revenue beat but an earnings per share miss at $0.07, presenting a mixed financial performance.

Analysis

UBS has upgraded Fulgent Genetics (FLGT) to Buy from Neutral, raising its price target by 50% to $30.00. The upgrade is predicated on several key factors, including the company's strong financial position, characterized by more cash than debt and a healthy current ratio of 6.0x. The investment bank identifies significant growth potential in Fulgent's Precision Diagnostics segment, which constitutes 60% of sales, citing share gain opportunities within a more favorable reimbursement environment. Furthermore, the Anatomic Pathology business, representing 35% of sales, is noted as having recovered and is no longer diluting growth. UBS forecasts sustained revenue growth of approximately 10% for 2025 and beyond, arguing that the current stock valuation fails to credit this trajectory. This positive outlook is tempered by the company's mixed Q2 2025 earnings, which saw revenue of $81.8 million exceed forecasts of $76.21 million, but reported an earnings per share of $0.07, described as a -138.89% surprise miss against an expected EPS of $-0.18. A potential long-term catalyst is the anticipated 2026 data from the FID-007 trial, which could trigger a reassessment of the company's pharmaceutical assets.

Key Decisions for Investors

• Investors may view the UBS upgrade and $30 price target as a strong positive signal, supported by the firm's outlook for 10% sustained revenue growth and a valuation that appears to discount this potential.
• It is critical to scrutinize the recent Q2 earnings report, where a strong revenue beat was accompanied by a significant reported EPS miss, in order to understand the underlying drivers of profitability.
• The company's robust balance sheet, with a 6.0x current ratio and more cash than debt, provides a degree of financial stability that could mitigate downside risk while awaiting the potential catalyst from the FID-007 trial data in 2026.